Effects of Caloric Restriction in Obesity and Type 2 Diabetes

Obesity Clinical Trial

— CRESO2  

Official title:

Long-term Effects of Caloric Restriction on Metabolic, Renal End Retinal Health in Subjectsaffected by Obesityand Type 2 Diabetes

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01930136
• Other study ID #: CRESO 2
• Status: Completed
• Phase: N/A
• Start date: May 2013
• Est. completion date: May 5, 2022

Study information

• Verified date: May 2022
• Source: Mario Negri Institute for Pharmacological Research
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study investigates whether a long-term 25% caloric restriction can prevent onset and/or progression of renal function deterioration, retinal involvement and cardiovascular complications in overweight/obese type 2 diabetic patients, trough the amelioration of concomitant metabolic abnormalities such as visceral obesity, insulin resistance, dyslipidemia, hypertension and inflammation.

The main aim of the study is therefore to evaluate the role of calorie restriction (CR) on subjects at risk of nephropathy. Secondary aims are to better understand the relationship between CR and the following aspects: renal disease and its associated metabolic abnormalities, retinopathy and cardiovascular complications, quality of life and treatment cost.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 103
• Est. completion date: May 5, 2022
• Est. primary completion date: May 5, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years and older

Eligibility

Inclusion Criteria

• Age >40 years;

• Type 2 diabetes (ADA criteria);

• UAE <300 mg/24h;

• Body mass index (BMI)>27kg/m2;

• Serum creatinine < 1.2 mg/dL;

• No major changes in calorie, protein and sodium intake in the last 6 mos;

• No major changes in concomitant treatments with blood pressure, glucose or lipid lowering agents since 6 and 3 months respectively;

• Patients legally able to give written informed consent to the trial (signed and dated by the patient);

• Written informed consent.

Exclusion Criteria

• Concomitant non-diabetic renal disease or ischemic kidney disease;

• Primary or immune-mediated renal disease;

• Urinary tract obstruction or infection;

• Treatment with steroids and/or non-steroid anti-inflammatory agents;

• Treatment with thiazide or loop diuretics that, on the basis of the Investigator's judgment, might sustain hypovolemia and/or sodium depletion (with secondary kidney hypoperfusion/hypofiltration);

• Hearth failure and/or hemodynamically significant left ventricular systolic dysfunction, cirrhosis, uncontrolled hyperglycemia resulting in glycosuria, hyper/hyponatremia of any cause;

• Previous surgical procedures for weight loss;

• Previous episodes of depression, or suicide attempts;

• Chronic abuse of alcohol and drugs;

• Pregnancy, ineffective contraception or peri-menopausal age;

• Cancer or any chronic disease that might affect the completion of the study;

• Chronic obstructive pulmonary disease (COPD) in treatment with positive airway pressure;

• Unwillingness or inability to adhere to CR intervention over the entire 24-months intervention period;

• Legal incapacity and/or other circumstances rendering the patient unable to understand the nature, scope and possible consequence of the trial;

• Evidence of an uncooperative attitude;

• Any evidence that patient will not be able to complete the trial follow-up;

• Inability to fully understand the potential risks and benefits of the study.

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 2
• Obesity
• Type 2 Diabetes

Intervention

Behavioral:
• Calorie restriction (25%)

• Ad libitum health diet

Locations

Country	Name	City	State
Italy	Clinical Research Center for Rare Diseases	Ranica	Bergamo

Sponsors (2)

Lead Sponsor	Collaborator
Mario Negri Institute for Pharmacological Research	Istituto Superiore di Sanità

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The percent change in glomerular filtration rate (GFR) at month 6 versus baseline and the rate of GFR decline from month 6 to study end		At baseline, 6, 12 and 24 month